366 related articles for article (PubMed ID: 33304355)
1. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
Vonderheide RH; Bear AS
Front Immunol; 2020; 11():605619. PubMed ID: 33304355
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells and their role in pancreatic cancer.
Pergamo M; Miller G
Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
[TBL] [Abstract][Full Text] [Related]
3. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
[TBL] [Abstract][Full Text] [Related]
5. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
7. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
Oweida AJ; Mueller AC; Piper M; Milner D; Van Court B; Bhatia S; Phan A; Bickett T; Jordan K; Proia T; Schulick R; Messersmith WA; Del Chiaro M; Clambey E; Gough MJ; Williams J; Hansen K; Goodman K; Karam SD
Cancer Immunol Immunother; 2021 Apr; 70(4):989-1000. PubMed ID: 33097963
[TBL] [Abstract][Full Text] [Related]
8. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
10. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.
Hartmann N; Giese NA; Giese T; Poschke I; Offringa R; Werner J; Ryschich E
Clin Cancer Res; 2014 Jul; 20(13):3422-33. PubMed ID: 24763614
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity.
Hezaveh K; Shinde RS; Klötgen A; Halaby MJ; Lamorte S; Ciudad MT; Quevedo R; Neufeld L; Liu ZQ; Jin R; Grünwald BT; Foerster EG; Chaharlangi D; Guo M; Makhijani P; Zhang X; Pugh TJ; Pinto DM; Co IL; McGuigan AP; Jang GH; Khokha R; Ohashi PS; O'Kane GM; Gallinger S; Navarre WW; Maughan H; Philpott DJ; Brooks DG; McGaha TL
Immunity; 2022 Feb; 55(2):324-340.e8. PubMed ID: 35139353
[TBL] [Abstract][Full Text] [Related]
12. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ
Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120
[TBL] [Abstract][Full Text] [Related]
13. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
14. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.
Alam MS; Gaida MM; Bergmann F; Lasitschka F; Giese T; Giese NA; Hackert T; Hinz U; Hussain SP; Kozlov SV; Ashwell JD
Nat Med; 2015 Nov; 21(11):1337-43. PubMed ID: 26479921
[TBL] [Abstract][Full Text] [Related]
16. The immune network in pancreatic cancer development and progression.
Wörmann SM; Diakopoulos KN; Lesina M; Algül H
Oncogene; 2014 Jun; 33(23):2956-67. PubMed ID: 23851493
[TBL] [Abstract][Full Text] [Related]
17. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
18. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
19. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma.
Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H
Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741
[TBL] [Abstract][Full Text] [Related]
20. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
